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Introduction
Increased total homocysteine in the blood "hyperhomocysteinemia" is an established risk 
factor for premature atherosclerotic disease in the coronary, cerebral and peripheral arteries [1]. 
Homocysteine is metabolized by either remethylation or trans-sulphuration. The former reaction 
is vitamin B12-dependent, occurs in all tissues and requires the enzyme methionine synthase. The 
latter reaction, which in general is relatively minor, is vitamin B12-independent, occurs mostly in 
the liver and requires a different enzyme-betaine homocysteine methyltransferase. [2]
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CLINICAL STUDIES
Abstract: Two common polymorphisms of the methylenetetrahydrofolate reductase (MTHFR) gene, the 
thermolabile C677T and A1298C polymorphism may contribute to hyperhomocysteinemia, a known risk factor 
for vascular diseases. Twenty with coronary artery disease (CAD) and 20 patients with cerebro-vascular stroke 
(CVS) were compared with 20 controls. Using PCR and restriction fragment length polymorphism (RFLP) 
analysis, we studied C677T and A 1298C MTHFR genotypes and their combined effect on homocysteine, 
measured by chemiluminescent enzymatic immunometric assay. Homocysteine values were significantly higher 
in CAD (16.12 ± 5.09 μmol/L) and in CVS (16.79 ± 5.93 μmol/L) compared with controls (10.43± 2.57 μmol/L, 
P<0.01). In C677T genotype, homocysteine was significantly higher in TT (18.26 ±2.75 μmol/L) and in CT 
(17.60 ± 7.22 μmol/L) than in CC genotype (12.94 ± 4.16 μmol/L, P<0.01). However, in A1298C genotype, no 
significant difference was found between the mean homocysteine level in AA genotype (14.14 ± 4.32 μmol/L), 
AC genotype (14.25 ± 5.50 μmol/L) and CC genotype patients (16.28 ± 8.76 μmol/L, P>0.05). A significant 
positive correlation between plasma homocysteine and cholesterol (r=0.37, P<0.01) and LDL-C levels was found
(r=0.321, P<0.05). The percentage of patients with high homocysteine level (t15 μmol/L) were significantly 
higher in CAD (50%) and CVS (55%) than controls (5%, P<0.01, odd ratio=21). In contrast to the A1298C 
polymorphism, the MTHFR TT and CT genotypes were associated with hyperhomocysteinemia. The knowledge 
of the MTHFR mutation (C677T) status might represent a way to identify subjects at high risk for 
hyperhomocysteinemia.
Key words: Homocysteine, Methylenetetrahydrofolate reductase polymorphism, C677T MTHFR genotypes, 
                     A1298C MTHFR genotypes.
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The enzyme MTHFR plays a critical role in homocysteine metabolism by catalyzing the 
conversion of 5, 10 methylenetetrahydrofolate to 5-methyltetrahydrofolate, the predominant 
circulatory form of folate and the methyl-group donor in the B12-dependent remethylation of 
homocysteine to methionine [3]. Severe deficiency of the MTHFR enzyme leads to 
homocystinuria, a rare inborn error of metabolism, characterized by highly increased blood and 
urine homocysteine concentrations [4].
Hyperhomocysteinemia is caused by acquired and genetic factors [5]. The human MTHFR 
gene has been mapped to chromosomal region 1p 36.3[6]. It has been recently demonstrated that 
two common mutations in the MTHFR gene, the cytosine-to-thymine substitution at base 677 
(C677T) and adenine-to-cytosine substitution at base 1298 (A1298C), creating a thermolabile 
enzyme variant and somewhat reduced enzyme activity in vitro. These two mutations predispose 
to hyperhomocysteinemia, especially in folate-deficient subjects Thermolabile MTHFR enzyme 
has been associated with increased incidence of early cardiovascular disease [2]. Determination of 
the MTHFR genotype will probably become a valuable screening test for assessment of 
cardiovascular risk in large populations [8]. We aimed to study the possible association between 
MTHFR genotypes and plasma homocysteine levels in one hand and the risk of occlusive arterial 
diseases including CAD and CVS in the other hand and comparing the incidence of different 
MTHFR genotypes in CAD and CVS patients with those genotypes in normal subjects.
Subjects and Methods
This study was conducted on 40 patients, 25 males and 15 females selected from Kasr El 
Aini Hospital Internal Medicine ICU Department after taking consents from all participants. They 
were divided into: Group (1) 20 CAD patients with history of cardiac catherterization and 
documented evidence of coronary artery atherosclerosis. Their age was 50.75r 6.52 years. Group 
(2) 20 CVS patients with cerebral infarction documented by CT brain. Their age was 51.65r 9.59 
years. Both groups were compared with 20 healthy control subjects, 12 males and 8 females, 
aged 48.15r 8.28 years.
Exclusion criteria included: patients with risk factors for atherosclerosis as cigarette 
smoking, diabetes mellitus, hypertension, abnormal lipid profile or abnormal renal function.
Specimen Collection: 10 ml of morning venous samples were collected after a 12 hour 
fast and aliquoted into 4 tubes under aseptic conditions from patients and controls as follows: 
sodium fluoride plasma for determination of glucose, serum for determination of the lipid profile 
(total cholesterol, HDL-C, LDL-C and triglycerides) and folic acid, and EDTA plasma for 
determination of homocysteine. The EDTA samples were stored on ice from the time of sampling 
and centrifugation. The plasma was then separated immediately to avoid falsely high values 
resulting from homocysteine leakage from the erythrocytes [9]. Sterile vacutainer tubes containing 
EDTA were used to store samples at -70oC for performing PCR for MTHFR gene study. 
The determination of glucose, and lipid profile tests were done on Hitachi 911 
autoanalyzer (Boehringer Mannheim GmbH 0-68298 Mannheim/Germany).
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Determination of homocysteine and folic acid were done by chemiluminescent enzymatic 
immunometric assay using the immulite automated analyzer. The kits were supplied by DPC 
(DPC Diagnostic products corporation 5700 West 96th Street Los Angeles, CA 90045-5597) [10, 
11].
DNA analysis for MTHR gene mutations (C677T) and (A1298C) was done by PCR8, 1. 
The test was done in 5 main steps:
1. Extraction of genomic DNA from peripheral blood leucocytes of EDTA anticoagulated 
blood. This was done using the salting out technique based on the method of Trowsdale [12].
2. Amplification of the extracted DNA by PCR using Taq polymerase enzyme and Hybaid 
thermal cycler (Promega Corporation, USA). Three primers were used to detect the C677T 
mutation in the MTHFR gene: referred to as forward (F), outer forward '(OF), and reverse 
(R). Their sequences were:
5'-GGAGCTTTGAGGCTGACC TGAA-3' (F). 
5'-TGAAGGAGAAGGTGTCTGCGGGA-3' (OF).
5'-AGGACGGTGCGGTGAGAGTG-3' (R).
A seminested protocol included the OF and R primers in the first reaction of 35 cycles; 
3μL of the first reaction was then transferred to the second reaction which consisted of 35 cycles 
with the F and R primers. Two primers were used to detect A1298C mutation in the MTHFR 
gene:
Sense, 5'-CTTCTACCTGAAGAGCAAGTC-3'.
Antisense, 5'-CATGTCCACAGCATCGAG-3'.
3. Detection of PCR amplification products using gel electrophoresis and ultraviolet light 
transillumination.
4. The amplified products were digested with the suitable restriction enzyme specific for the 
mutation (Mbo II for A1298C and Hinf I for C677T).
5. The amplified products after digestion were then analyzed by electrophoresis on agarose gel 
containing ethidium bromide, and visualized by ultraviolet transilluminator for identification 
of the point mutations in the MTHFR gene.
Statistical analyses of the data were performed by one way ANOVA using (SPSS® for 
Windows version 8 software). The 0.05 level of probability was used as the criterion for 
statistical significance. 
Results
Table 1 shows the comparison between different studied groups which were age matched. 
The mean total cholesterol values were not abnormally elevated in the patient groups, however 
they were significantly   higher   in   group 1   (166.5± 14.88ng/dl)   and in group 2 
(162.65±22.53 mg/dl) than in the control group (143.25± 19.04 mg/dl, p<0.01). Similar results 
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were found concerning LDL-C (88.25±16.20 mg/dl for group 1, 84.85±22.99 mg/dl for group 2 
and 64.30±18.85 mg/dl for control group, p<0.01). There was no significant difference between 
all groups as regards HDL-C mean values (48.45±3.47 mg/dl for group 1, 49.80±4.12 mg/dl for 
group 2 and 51.30± 5.04 mg/dl for control group, p>0.05) or triglyceride mean values 
(149.55±24.46 mg/dl for group 1, 140.35±24.12 mg/dl for group 2 and 138.15±29.36 mg/dl for 
control group, p>0.05). Table 1 also shows  that the mean homocysteine values were significantly 
higher in CAD patients (16.12 ± 5.09 μmol/L) and in CVS patients (16.79 ± 5.93 μmol/L) 
compared with control group (10.43± 2.57 μmol/L) (P<0.01). Meanwhile the mean values of 
folic acid showed no significant difference between all groups (5.84±3.05 ng/ml for group 1, 
6.91±4.47 ng/ml for group 2 and 6.20± 2.49 ng/ml for control group, p>0.05).
Table 1: Comparison between different parameters in the studied groups
Parameters Group 1: CAD
N=20
Group 2: CVS
N=20
Control group
N=20
Age: years 50.75r 6.52 a 51.65r 9.59 a 48.15r 8.28 a
Total Cholesterol mg/dl 166.5± 14.88 a 162.65±22.53 a 143.25± 19.04 b
LDL mg/dl 88.25±16.20 a 84.85±22.99 a 64.30±18.85 b
HDL-C mg/dl 48.45±3.47 a 49.80±4.12 a 51.30± 5.04 a
Triglycerides mg/dl 149.55±24.46 a 140.35±24.12 a 138.15±29.36 a
Homocysteine μmol/L 16.12 ± 5.09 a 16.79± 5.93 a 10.43± 2.57 b
Folic acid ng/ml 5.84±3.05 a 6.20±2.49 a 6.91±4.47 a
Valuess sharing the same letters do not differ from each other at p=0.05 degree of significance
Values with different letters differ significantly at p<0.01
CAD: Coronary artery disease CVS: Cerebrovascular stroke
LDL-c: Low density lipoprotein cholesterol HDL-c: High density lipoprotein cholesterol
Comparison was done using ANOVA test. Groups sharing the same letters do not differ from 
one another at p=0.05 degree of significance.
Table 2 shows the comparison of homocysteine level in C677T and A1298C genotypes. 
In C677T genotype, homocysteine level was significantly higher in TT genotype subjects (18.26 
±2.75 μmol/L) and CT genotype subjects (17.60 ± 7.22 μmol/L) as compared with CC genotype 
subjects (12.94 ± 4.16 μmol/L, P<0.01). However in A1298C genotype, no significant difference 
was found between the mean homocysteine level in AA genotype (14.14 ± 4.32 μmol/L), AC 
genotype (14.25 ± 5.50 μmol/L) and CC genotype (16.28 ± 8.76 μmol/L) (P>0.05).
Table 2: Comparison of homocysteine level (μmol/L) in C677T and A1298C genotypes
CC CT TTC677T
 genotype 12.94 ± 4.16 b 17.60 ± 7.22 a 18.26 ±2.75 a
AA AC CCA1298C 
genotype 14.14 ± 4.32 a 14.25 ± 5.50 a 16.28 ± 8.76 a
                       Valuess sharing the same letters do not differ from each other at p=0.05 degree of significance
                       Values with different letters differ significantly at p<0.01
                       A: Adenine, C: Cytosine, T: Thymine 
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Table 3 shows the genotype frequency in different studied groups. As regards the C677T,   
the CC frequency was significantly lower in CAD patients (60%) as compared with control group 
(75% with p<0.05). The CT frequency was significantly higher in CAD (35%) as compared with 
CVS patients (20%) with p<0.01. The TT genotype frequency was significantly higher in CAD 
(5%) and CVS patients (10%) as compared with control group (0%, P<0.05, <0.01 respectively). 
As regards the A1298C, the AA frequency was significantly higher in CVS patients 
(45%) as compared with control group (30%, p<0.05). The AC frequency was significantly lower 
in CVS (45%) as compared with control group (60%, p<0.05). The CC genotype frequency was 
not significantly different in all groups (15%, 10%, and 10% respectively; P>0.05). 
                       
                                                     Table 3:  The genotype frequency in different studied groups
      Group 1: CAD
             N=20
      Group 2: CVS
             N=20
            Control group
                  N=20       Genotypes Frequency       % Frequency     % Frequency           %
C677T
genotype
CC
CT
TT
    12/20
      7/20
      1/20
   60% a
   35% a
    5% a
    14/20
    4/20
     2/20
  70% ab
  20% b
  10% a
       15/20
         5/20
         0/20
       75% b
       25% ab
         0% b
A1298C
genotype
AA
AC
CC
      8/20
      9/20
      3/20
   40% ab
   45% ab
   15% a
     9/20
     9/20
     2/20
  45% b
  45% b
  10% a
         6/20
       12/20
         2/20
       30% a
       60% a
       10% a
       Values sharing the same letters do not differ from each other at p=0.05 degree of significance
       Values with different letters differ significantly from control at p<0.05
       CAD: Coronary artery disease CVS: Cerebrovascular stroke
        A: Adenine, C: Cytosine, T: Thymine
Table 4 outlines the C677T and A1298C allele frequency in different studied groups. The 
frequency of C allele was significantly higher in the control group (85.5%) as compared with 
CAD patients (77.5%, p<0.05). The T allele frequency was significantly higher in CAD patients 
(22.5%) as compared with control group (12.5%, p<0.05). There was no significant difference 
between the frequency of A and C alleles in all groups under study (62.5%, 67.5%, 60% 
respectively for A and 37.5%, 32.5%, 40% respectively for C, p>0.05). 
                                     Table 4: The C677T and A1298C allele frequency in different studied groups
Group 1: CAD
N=20
Group 2: CVS
N=20
Control group
N=20Genotypes Frequency % Fequency % Frequency %
C
T
15.5/20
4.5/20
77.5% a
22.5% a
16/20
4/20
80% ab
20% ab
17.5/20
2.5/20
85.5% b
12.5% b
A
C
12.5/20
7.5/20
62.5% a
37.5% a
13.5/20
6.5/20
67.5% a
32.5% a
12/20
8/20
60% a
40% a
       Values sharing the same letters do not differ from each other at p=0.05 degree of significance
       Values with different letters differ significantly from control at p<0.05.
      CAD: Coronary artery disease CVS: Cerebrovascular stroke
      A: Adenine, C: Cytosine, T: Thymine
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Table 5 demonstrated that the percentage of patients with high homocysteine level 
(t15 μmol/L) were significantly higher in CAD (50%) and in CVS patients (55%) as 
compared with control group (5%, P<0.01). Table 5 also shows that the Odds ratio (OR) of 
homocysteine was 21; confirming that a patient who has CAD or CVS is about 21 times 
more likely to have high homocysteine level than a patient who does not have CAD or CVS. 
Table 5: The percentage of patients with high homocysteine level (cut off=15
    μmol/L) and odd ratio (OR) in the different studied groups
Group 1: 
CADN=20
Group 2: 
CVSN=20
All patients
N=40
Control group
N=20 OR
Homocyste
ine level
cut off=15 
μmol/L
Frequency/% Frequency/% Frequency/%   Frequency/% P
value
Normal 10/20
50% a
9/20
45% a
19/40
47.5%a
19/20
95% b
<0.01
High 10/20
50% a
11/20
55% a
21/40
52.5%
1/20
5% b
<0.01
 21
Groups sharing the same letters do not differ from each other at p=0.05 degree of significance
CAD: Coronary artery disease CVS: Cerebrovascular stroke
OR : Odd ratio(data are not shown).
A significant positive correlation was found between plasma homocysteine and total 
cholesterol (r=0.37, P<0.01), and LDL-C levels (r=0.32, P<0.05), but there was insignificant 
negative correlation between plasma homocysteine and folic acid concentrations (r=- 0.221), 
P>0.05.
Discussion
In this study, the mean homocysteine values were significantly higher in CAD 
patients (16.12 r 5.09 μmol/L) and in CVS patients (16.79 r 5.93 μmol/L) compared with 
control group (10.43 r 2.57 μmol/L) with a P value <0.01. Similar results were obtained by 
other workers in CVS patients [13], CAD patients [14, 15] and both CVS and CAD patients [16]. 
These findings could be explained by the relationship between homocysteine and occlusive 
vascular disease. Homocysteine and its metabolites might act as thrombogenic agents by 
affecting the expression of the thrombomodulin, activation of protein C, increased platelet 
aggregation and thromboxane production. Furthermore the oxidation of homocysteine may 
result in the formation of hydrogen peroxide and free radicals, promoting the oxidation of 
LDL-C and damaging the endothelial lining, key components in the process of 
atherosclerosis. On the other hand, other workers [17-20] found no significant difference 
between the mean homocysteine concentrations in patients with CVS or CAD and control 
subjects. This might be due to variations in MTHFR genotypes. 
The present study reveals that the mean values of homocysteine were dependent on 
MTHFR genotype. Homocysteine in patients with TT genotype (18.26 r 2.75 μmol/L) and 
CT genotype subjects (17.60 r 7.22 μmol/L) were significantly higher as compared to 
patients with CC genotype (12.94 r 4.16 μmol/L, P<0.01), however no significant difference 
was found between TT and CT genotypes (P>0.05). This is in accordance with the findings 
of other workers [21-23]. These results indicate a strong graded association between 
homocysteine and vascular risk in TT and CT genotype
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while CC is a protective genotype and MTHFR genotype is a key determinant of plasma 
homocysteine concentrations. In this study, there was no significant difference between the 
mean values of homocysteine in AA genotype (14.14 r 4.32 μmol/L), AC genotype (14.2S r
5.50 μmol/L) and CC genotype (16.28 r 8.76 μmol/L, P>0.05). This is in accordance with 
other workers [8, 24, 25] who observed that there was no significant difference in mean 
homocysteine concentrations in individuals who were either heterozygous carries or 
homozygous for the 1298C allele compared with individuals homozygous for the 1298A 
allele. This means that the 1298 AoC mutation may has no significant influence on plasma 
homocysteine levels, thus cannot predispose to vascular parameters.
A significant positive correlation between plasma homocysteine and LDL-C levels was 
found in this current study (r= 0.321, p<0.05). Girelli and associates [14] reaffirmed the same 
findings.  This finding leads to the suggestion that both LDL-C and homocysteine are 
atherogenic. The atherogenicity of LDL-C had been well established very long ago and its 
positive correlation with plasma homocysteine levels draws the attention to the possible effect 
of high homocysteine levels in different vascular parameters.
In this study, there was insignificant negative correlation between plasma 
homocysteine and folic acid concentrations (r=-0.221, P>0.05). In agreement with this study, 
was the study of Andreassi and co-workers [23]. Other authors had reported a significant 
negative correlation between plasma homocysteine and folate levels [8, 26]. This could be 
explained by the importance of folate in the remethylation of homocysteine to methionine.
As regards the 677T allele frequency, similar to other workers [27], it was significantly 
higher in CAD group (22.5%) as compared to control group (12.5%, P<0.05). This result 
could be explained by the possible association between 677T allele and risk of vascular 
diseases. However, 
this finding was not found by Pinto and associates [28] who reported that the TT genotype was 
associated with hyperhomocysteinemia,  not with CAD.
In this study, there was no significant difference between the frequency of 1298 A and 
C alleles in CAD (62.5% and 37.5%), CVS (67.5% and 32.5%) and control group (60% and 
40% respectively, P>0.05). Other workers [29, 30] also found that there was no evidence to 
suggest an association between A1298C MTHFR mutation and occlusive vascular diseases. 
However, in contrast to this study, was the study of Szczeklik who found that the frequency of 
the 1298C allele was significantly higher in CAD than in control subjects [31].
In this study, similar to the published data [27, 32], it was found that the TT genotype 
frequency was significantly higher in CAD patients (5%) and CVS patients (10%) as 
compared with control (0%, p<0.05, p<0.01 respectively). These data support the suggestion 
that there is an association between TT genotype of the human MTHFR gene and the 
development of vascular diseases. However, these findings were not detected by other authors
[18, 33].
Similar to other studies, [19, 34] we recorded no statistically significant difference 
between the frequency of 1298CC genotype in CHD or CVD patients (15%, 10% respectively) 
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when compared with control group (10%, p>0.05). These findings suggest that the frequency 
of 1298 C allele and its homozygous state are not associated with various vascular diseases. 
However further studies are required to determine this association.
We also observed that the percentage of patients with plasma homocysteine level >15 
μmol/L was significantly higher in CAD group (50%) and in CVS group (55%) than in control 
group (5%, P<0.01). These results support the findings of previous studies [35, 36] that showed 
that hyperhomocysteinemia has a strong effect on the pathogenesis of various vascular 
diseases. We studied the risk ratio for plasma homocysteine and it was found that plasma 
homocysteine concentration above 15 μmol/L was a significant and independent risk factor for 
CAD and CVS (P<0.01, risk ratio 21). This means that a patient who has CAD or GVS is 
about 21 times more likely to have high homocysteine level than a patient who does not have 
CAD or CVS. This was also recorded by other authors [17, 35]. 
In conclusion, homocysteinemia above 15 μmol/L could be considered as an 
independent risk factor for different vascular diseases, by promoting both atherosclerosis and 
thrombosis through causing endothelial injury, smooth muscle cell proliferation and LDL-C 
oxidation. The MTHFR TT and CT genotypes were associated with hyperhomocysteinemia. 
In contrast to the C677T polymorphism, the A1298C polymorphism was not associated with 
increased plasma homocysteine. Although the direct measurement of plasma homocysteine 
levels should remain the primary goal, the knowledge of the MTHFR mutation (C677T) status 
might be of some value when patients with vascular disease are investigated. This approach 
might represent an alternative way to identify subjects at high risk for hyperhomocysteinemia.
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